analyzed post-treatment biopsy specimens from 17 metastatic melanoma patients with ICB treated, and they found the percentage of heterozygous deletions and point mutations of B2M was 9.4%, which suggested that B2M loss may be a common mechanism of resistance to targeted CTLA-4 or PD-1 therapy (121). Here, B2M is linked to metastatic melanoma.